tbuckley/cabot-search huggingface dataset:
An 8-gene machine learning model improves clinical prediction of severe dengue progression
Authors: Yiran E. Liu, Sirle Saul, Aditya Manohar Rao, Makeda Lucretia Robinson, Olga Lucia Agudelo Rojas, Ana Maria Sanz, Michelle Verghese, Daniel Solis, Mamdouh Sibai, Chun Hong Huang, Malaya Kumar Sahoo, Rosa Margarita Gelvez, Nathalia Bueno, Maria Isabel Estupiñan Cardenas, Luis Angel Villar Centeno, Elsa Marina Rojas Garrido, Fernando Rosso, Michele Donato, Benjamin A. Pinsky, Shirit Einav, Purvesh Khatri
Journal: Genome Medicine (2022)

Each year 3-6 million people develop life-threatening severe dengue (SD). Clinical warning signs for SD manifest late in the disease course and are nonspecific, leading to missed cases and excess hospital burden. Better SD prognostics are urgently needed.We integrated 11 public datasets profiling the blood transcriptome of 365 dengue patients of all ages and from seven countries, encompassing biological, clinical, and technical heterogeneity. We performed an iterative multi-cohort analysis to identify differentially expressed genes (DEGs) between non-severe patients and SD progressors. Using only these DEGs, we trained an XGBoost machine learning model on public data to predict progression to SD. All model parameters were "locked" prior to validation in an independent, prospectively enrolled cohort of 377 dengue patients in Colombia. We measured expression of the DEGs in whole blood samples collected upon presentation, prior to SD progression. We then compared the accuracy of the locked XGBoost model and clinical warning signs in predicting SD.We identified eight SD-associated DEGs in the public datasets and built an 8-gene XGBoost model that accurately predicted SD progression in the independent validation cohort with 86.4% (95% CI 68.2-100) sensitivity and 79.7% (95% CI 75.5-83.9) specificity. Given the 5.8% proportion of SD cases in this cohort, the 8-gene model had a positive and negative predictive value (PPV and NPV) of 20.9% (95% CI 16.7-25.6) and 99.0% (95% CI 97.7-100.0), respectively. Compared to clinical warning signs at presentation, which had 77.3% (95% CI 58.3-94.1) sensitivity and 39.7% (95% CI 34.7-44.9) specificity, the 8-gene model led to an 80% reduction in the number needed to predict (NNP) from 25.4 to 5.0. Importantly, the 8-gene model accurately predicted subsequent SD in the first three days post-fever onset and up to three days prior to SD progression.The 8-gene XGBoost model, trained on heterogeneous public datasets, accurately predicted progression to SD in a large, independent, prospective cohort, including during the early febrile stage when SD prediction remains clinically difficult. The model has potential to be translated to a point-of-care prognostic assay to reduce dengue morbidity and mortality without overwhelming limited healthcare resources.
SCREENING OVER 100,000 PATIENTS IN 39 GENERAL PRACTICES IN THE NETHERLANDS FOR ANTICOAGULATION UNDERTREATMENT IN ATRIAL FIBRILLATION
Authors: Leonard Voorhout, Ron Pisters, Constants H. Geurts, Andrew Oostindjer, Sander van Doorn, Harrie Rila, Wessel W. Fuijkschot, Freek W.A. Verheugt, Martin E.W. Hemels
Journal: Journal of the American College of Cardiology (2022)
A New IMiD for Systemic Lupus Erythematosus — Tempering Our Excitement
Authors: Karen H. Costenbader
Journal: New England Journal of Medicine (2022)

When phase 2 trials of treatments for systemic lupus erythematosus (SLE) show positive results, I am delighted but try not to get my hopes up; there have been too many phase 3 trial failures. However, the recent Food and Drug Administration approval of voclosporin and belimumab for lupus nephritis and anifrolumab for nonrenal SLE have put wind in the sails of the SLE community. These are the first approvals of new medications for the treatment of SLE since the 2011 approval of belimumab for nonrenal SLE and the 1955 approval of hydroxychloroquine. Lupus is a paradigmatic autoimmune disease, and its . . .
Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study
Authors: Devin B. Phillips, Amany F. Elbehairy, Matthew D. James, Sandra G. Vincent, Kathryn M. Milne, Juan P. de-Torres, J. Alberto Neder, Miranda Kirby, Dennis Jensen, Michael K. Stickland, Jordan A. Guenette, Benjamin M. Smith, Shawn D. Aaron, Wan C. Tan, Jean Bourbeau, Denis E. O’Donnell, Jonathon Samet, Milo Puhan, James C. Hogg, Qutayba Hamid, Dany Doiron, Palmina Mancino, Pei-Zhi Li, Zhi Song, Yvan Fortier, Kenneth Chapman, Patricia McClean, Jane Duke, Andrea S. Gershon, Teresa Toh, Mohsen Sadatsafavi, Don Sin, J. Mark Fitzgerald, Jeremy Road, Christine Lo, Sarah Cheng, Elena Un, Michael Cheng, Cynthia Fung, Faize Faroon, Olga Radivojevic, Sally Chung, Carl Zou, Rena Choi, Joe Comeau, Harvey Coxson, Miranda Kirby, Jonathon Leipsic, Cameron Hague, Brandie Walker, Curtis Dumonceaux, Paul Hernandez, Scott Fulton, Kathy Vandemheen, Matthew McNeil, Kate Whelan, Francois Maltais, Cynthia Brouillard, Darcy Marciniuk, Ron Clemens, Janet Baran
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: Impaired exercise ventilatory efficiency (high ventilatory requirements for CO2 [V˙e/V˙co2]) provides an indication of pulmonary gas exchange abnormalities in chronic obstructive pulmonary disease (COPD). Objectives: To determine 1) the association between high V˙e/V˙co2 and clinical outcomes (dyspnea and exercise capacity) and its relationship to lung function and structural radiographic abnormalities; and 2) its prevalence in a large population-based cohort. Methods: Participants were recruited randomly from the population and underwent clinical evaluation, pulmonary function, cardiopulmonary exercise testing, and chest computed tomography. Impaired exercise ventilatory efficiency was defined by a nadir V˙e/V˙co2 above the upper limit of normal (ULN), using population-based normative values. Measurements and Main Results: Participants included 445 never-smokers, 381 ever-smokers without airflow obstruction, 224 with Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 COPD, and 200 with GOLD 2–4 COPD. Participants with V˙e/V˙co2 above the ULN were more likely to have activity-related dyspnea (Medical Research Council dyspnea scale ⩾ 2; odds ratio [5–95% confidence intervals], 1.77 [1.31 to 2.39]) and abnormally low peak V˙o2 (V˙o2peak below the lower limit of normal; odds ratio, 4.58 [3.06 to 6.86]). The Kco had a stronger correlation with nadir V˙e/V˙co2 (r = −0.38; P < 0.001) than other relevant lung function and computed tomography metrics. The prevalence of V˙e/V˙co2 above the ULN was 24% in COPD (similar in GOLD 1 and 2 through 4), which was greater than in never-smokers (13%) and ever-smokers (12%). Conclusions: V˙e/V˙co2 above the ULN was associated with greater dyspnea and low V˙o2peak and was present in 24% of all participants with COPD, regardless of GOLD stage. The results show the importance of recognizing impaired exercise ventilatory efficiency as a potential contributor to dyspnea and exercise limitation, even in mild COPD.
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors
Authors: Enrico Ruffini, Ramon Rami-Porta, James Huang, Usman Ahmad, Sarit Appel, Andrea Bille, Souheil Boubia, Cecilia Brambilla, Ayten Kayi Cangir, Vanessa Cilento, Frank Detterbeck, Conrad Falkson, Wentao Fang, Pier Luigi Filosso, Giuseppe Giaccone, Nicolas Girard, Francesco Guerrera, Maurizio Infante, Dong Kwan Kim, Marco Lucchi, Mirella Marino, Edith M Marom, Andrew G Nicholson, Meinoshin Okumura, Andreas Rimner, Charles B Simone, Hisao Asamura
Journal: Journal of Thoracic Oncology (2022)
AN UNUSUAL CAUSE OF HIGH-OUTPUT HEART FAILURE FROM THE ARTERIOVENOUS FISTULA OF ILIAC ARTERY AFTER LUMBAR DISCECTOMY
Authors: Paisit Kosum, Suchat Sricholwattana, Suphot Srimahachota, Monravee Tumkosit, Pairoj Chattranukulchai, Smonporn Boonyarattavej
Journal: Journal of the American College of Cardiology (2022)
Clinical management of infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: A nationwide survey of tertiary hospitals in mainland China
Authors: Lei Zha, Shirong Li, Zhichu Ren, Xiang Li, Dayan Zhang, Yi Zou, Lingling Pan, Qiancheng Xu, Zuqin Rui, Shanghua Chen, Gang Yang, Zhixiang Chen, Boris Tefsen, Jun Guo
Journal: Journal of Infection (2022)
Child maltreatment, anxiety and depression, and asthma among British adults in the UK Biobank
Authors: Yueh-Ying Han, Qi Yan, Wei Chen, Juan C. Celedón
Journal: European Respiratory Journal (2022)

Child maltreatment is associated with asthma in adults. We examined whether lifetime major depressive disorder (MDD) or lifetime generalised anxiety disorder (GAD) mediate an association between child maltreatment and current asthma among 81 105 British adults in the UK Biobank who completed a mental health survey and had complete data on child maltreatment, GAD, MDD, asthma and relevant covariates but no diagnosis of chronic obstructive pulmonary disease.Child maltreatment was ascertained based on answers to the five questions in the Childhood Trauma Screener. Two mediators, lifetime MDD and GAD, were assessed based on the Composite International Diagnostic Interview Short Form. Current asthma was defined as physician-diagnosed asthma and wheeze or whistling in the chest in the previous year. Logistic regression was used for the multivariable analysis of child maltreatment and current asthma, and a mediation analysis was conducted to estimate the contributions of lifetime MDD and lifetime GAD to the child maltreatment-current asthma association.In a multivariable analysis, any child maltreatment was associated with asthma (adjusted OR 1.22, 95% CI 1.15-1.28; p<0.01). In a mediation analysis adjusted for household income, educational attainment, smoking status, pack-years of smoking and other covariates, lifetime GAD and lifetime MDD explained 21.8% and 32.5%, respectively, of the child maltreatment-current asthma association. Similar results were obtained after excluding current smokers and former smokers with ≥10 pack-years of smoking from the mediation analysis.Our findings suggest that GAD and MDD mediate an association between child maltreatment and asthma in adults, independently of smoking.
Metabolome-Defined Obesity and the Risk of Future Type 2 Diabetes and Mortality
Authors: Filip Ottosson, Einar Smith, Ulrika Ericson, Louise Brunkwall, Marju Orho-Melander, Salvatore Di Somma, Paola Antonini, Peter M. Nilsson, Céline Fernandez, Olle Melander
Journal: Diabetes Care (2022)

OBJECTIVE Obesity is a key risk factor for type 2 diabetes; however, up to 20% of patients are normal weight. Our aim was to identify metabolite patterns reproducibly predictive of BMI and subsequently to test whether lean individuals who carry an obese metabolome are at hidden high risk of obesity-related diseases, such as type 2 diabetes. RESEARCH DESIGN AND METHODS Levels of 108 metabolites were measured in plasma samples of 7,663 individuals from two Swedish and one Italian population-based cohort. Ridge regression was used to predict BMI using the metabolites. Individuals with a predicted BMI either &amp;gt;5 kg/m2 higher (overestimated) or lower (underestimated) than their actual BMI were characterized as outliers and further investigated for obesity-related risk factors and future risk of type 2 diabetes and mortality. RESULTS The metabolome could predict BMI in all cohorts (r2 = 0.48, 0.26, and 0.19). The overestimated group had a BMI similar to individuals correctly predicted as normal weight, had a similar waist circumference, were not more likely to change weight over time, but had a two times higher risk of future type 2 diabetes and an 80% increased risk of all-cause mortality. These associations remained after adjustments for obesity-related risk factors and lifestyle parameters. CONCLUSIONS We found that lean individuals with an obesity-related metabolome have an increased risk for type 2 diabetes and all-cause mortality compared with lean individuals with a healthy metabolome. Metabolomics may be used to identify hidden high-risk individuals to initiate lifestyle and pharmacological interventions.
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
Authors: Max O Meneveau, Pankaj Kumar, Kevin T Lynch, Sapna P Patel, Craig L Slingluff
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background A goal of cancer vaccines is to induce strong T cell responses to tumor antigens, but the delivery method, schedule, and formulation of cancer vaccines have not yet been optimized. Adjuvants serve to increase the immune response against vaccine antigens. However, little is known about the impact of adjuvants plus antigen and their delivery schedule on the immunologic milieu in the vaccine-site microenvironment (VSME). We hypothesized that antigen processing and presentation may occur directly in the VSME, that adding the toll-like receptor 3 (TLR3) agonist polyICLC (pICLC) would enhance markers of immune activation, and that the immune signatures would be enhanced further by repeated vaccination in the same skin site rather than after multiple vaccines in different skin locations. Methods Using RNA sequencing, we evaluated VSME biopsies from patients undergoing subcutaneous/intradermal peptide vaccination against melanoma, with incomplete Freund’s adjuvant (IFA) with or without pICLC. Differential gene expression analyses and gene set enrichment analyses were performed using R. False discovery rate corrected p values &lt;0.05 were considered significant. Results We found that addition of peptide antigens to IFA enhanced antigen presentation pathways and a tertiary lymphoid structure gene-signature locally at the VSME. Addition of pICLC to IFA + peptide induced an immunologically favorable VSME 1 week after injection but had little impact on the VSME after three injections, compared with IFA + peptide alone. Repeated same-site injection of IFA + peptide antigens induced a VSME with more dendritic cell activation, Th1 dominance, and TLR adaptor protein gene expression than that induced by injections at different, rotating skin locations. Conclusions These data suggest that the vaccine-site itself may be a critically important location contributing to vaccine immunity rather than just the draining lymph node, that IFA induces a favorable VSME with TLR agonist being most beneficial early in the vaccine course, and that same-site injections lead to persistent stimulation of immune pathways that may be beneficial in eliciting antigen specific T cell expansion.
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
Authors: Kristin G Anderson, Shannon K Oda, Breanna M Bates, Madison G Burnett, Magdalia Rodgers Suarez, Susan L Ruskin, Philip D Greenberg
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background In the USA, more than 50% of patients with ovarian cancer die within 5 years of diagnosis, highlighting the need for therapeutic innovations. Mesothelin (MSLN) is a candidate immunotherapy target; it is overexpressed by ovarian tumors and contributes to malignant/invasive phenotypes, making tumor antigen loss disadvantageous. We previously showed that MSLN-specific T cell receptor (TCR)-engineered T cells preferentially accumulate within established tumors, delay tumor growth, and significantly prolong survival in the ID8 VEGF mouse model that replicates many aspects of human disease. However, T cell persistence and antitumor activity were not sustained. We therefore focused on Fas/FasL signaling that can induce activation-induced cell death, an apoptotic mechanism that regulates T cell expansion. Upregulation of FasL by tumor cells and tumor vasculature has been detected in the tumor microenvironment (TME) of human and murine ovarian cancers, can induce apoptosis in infiltrating, Fas (CD95) receptor-expressing lymphocytes, and can protect ovarian cancers from tumor-infiltrating lymphocytes. Methods To overcome potential FasL-mediated immune evasion and enhance T cell responses, we generated an immunomodulatory fusion protein (IFP) containing the Fas extracellular binding domain fused to a 4-1BB co-stimulatory domain, rather than the natural death domain. Murine T cells were engineered to express an MSLN-specific TCR (TCR 1045 ), alone or with the IFP, transferred into ID8 VEGF tumor-bearing mice and evaluated for persistence, proliferation, cytokine production and efficacy. Human T cells were similarly engineered to express an MSLN-specific TCR (TCR 530 ) alone or with a truncated Fas receptor or a Fas-4-1BB IFP and evaluated for cytokine production and tumor lysis. Results Relative to murine T cells expressing only TCR 1045 , T cells expressing both TCR 1045 and a Fas-4-1BB IFP preferentially persisted in the TME of tumor-bearing mice, with improved T cell proliferation and survival. Moreover, TCR 1045 /IFP + T cells significantly prolonged survival in tumor-bearing mice, compared with TCR 1045 -only T cells. Human T cells expressing TCR 530 and a Fas-4-1BB IFP exhibit enhanced functional activity and viability compared with cells with only TCR 530 . Conclusions As many ovarian tumors overexpress FasL, an IFP that converts the Fas-mediated death signal into pro-survival and proliferative signals may be used to enhance engineered adoptive T cell therapy for patients.
COMPARING OUTCOMES OF PATIENTS WITH PRIMARY CARDIAC DIAGNOSES ADMITTED TO CARDIAC AND NON-CARDIAC INTENSIVE CARE UNITS: AN ARGUMENT FOR THE EVOLUTION OF CICU STAFFING MODELS
Authors: Samuel Brusca, Panagis Galiatsatos, Sarah Warner, Xiaobai Li, Tiffany Powell-Wiley, Sameer Kadri, Michael A. Solomon
Journal: Journal of the American College of Cardiology (2022)
Autoimmune Obsessive-Compulsive Disorder with Novel Anti-Basal Ganglia Antibodies
Authors: Dominique Endres, Lydia Mertens, Benjamin Berger, Marco Reisert, Kimon Runge, Kathrin Nickel, Katharina Domschke, Miriam A. Schiele, Horst Urbach, Nils Venhoff, Harald Prüss, Ludger Tebartz van Elst
Journal: Psychotherapy and Psychosomatics (2022)
25P Impact of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (the MEMOIR study): A propensity score-matched analysis
Authors: D.C. Qian, T. Kleber, B. Brammer, K.M. Xu, J.M. Switchenko, J.R. Janopaul-Naylor, J. Zhong, M.L. Yushak, R.D. Harvey, C.M. Paulos, D.H. Lawson, M.K. Khan, R.R. Kudchadkar, Z.S. Buchwald
Journal: Annals of Oncology (2022)
ORAL ANTICOAGULATION IN HOSPITALIZED PATIENTS WITH COVID-19, IS IT BENEFICIAL OR HARMFUL ?
Authors: Akhil Reddy Gade, Som Aftabi Bailey, Anand Subramanian, Nethuja Salagundla, Chandralekha Ashangari, Seline Haci, Senthil Thambidorai, Giridhar D. Mundluru
Journal: Journal of the American College of Cardiology (2022)
LIPOPROTEIN (A) IS ELEVATED IN PSORIATIC DISEASE AND ASSOCIATED WITH CARDIOVASCULAR RISK
Authors: Michael Seth Garshick, Kamelia Drenkova, Stuart Katz, Brittany Weber, Howard S. Weintraub, Arthur Schwartzbard, Rebecca Haberman, Edward A. Fisher, Andrea Neimann, Jose Scher, Jeffrey S. Berger
Journal: Journal of the American College of Cardiology (2022)
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
Authors: Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, Xuanling Che, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li, Xiaoming Zhou, Jianxun Song, Xingcong Ren, Wenjun Yi, Jinming Yang, Xiang Chen, Mingzhu Yin, Yan Cheng
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Immune checkpoint blockade (ICB) targeting programmed death ligand-1 (PD-L1)/programmed cell death protein-1 (PD-1) pathway has become an attractive strategy for cancer treatment; however, unsatisfactory efficacy has limited its clinical benefits. Therefore, a more comprehensive understanding of the regulation of PD-L1 expression is essential for developing more effective cancer immunotherapy. Recent studies have revealed the important roles of eukaryotic elongation factor 2 kinase (eEF2K) in promoting epithelial-mesenchymal transition (EMT), angiogenesis, tumor cell migration and invasion; nevertheless, the exact role of eEF2K in the regulation of tumor immune microenvironment (TIME) remains largely unknown. Methods In this study, we used a cohort of 38 patients with melanoma who received anti-PD-1 treatment to explore the association between eEF2K expression and immunotherapy efficacy against melanoma. Immunoprecipitation-mass spectrometry analysis and in vitro assays were used to examine the role and molecular mechanism of eEF2K in regulating PD-L1 expression. We also determined the effects of eEF2K on tumor growth and cytotoxicity of CD8 + T cells in TIME in a mouse melanoma model. We further investigated the efficacy of the eEF2K inhibition in combination with anti-PD-1 treatment in vivo. Results High eEF2K expression is correlated with better therapeutic response and longer survival in patients with melanoma treated with PD-1 monoclonal antibody (mAb). Moreover, eEF2K protein expression is positively correlated with PD-L1 protein expression. Mechanistically, eEF2K directly bound to and inactivated glycogen synthase kinase 3 beta (GSK3β) by phosphorylating it at serine 9 (S9), leading to PD-L1 protein stabilization and upregulation, and subsequently tumor immune evasion. Knockdown of eEF2K decreased PD-L1 expression and enhanced CD8 + T cell activity, thus dramatically attenuating murine B16F10 melanoma growth in vivo. Clinically, p-GSK3β/S9 expression is positively correlated with the expressions of eEF2K and PD-L1, and the response to anti-PD-1 immunotherapy. Furthermore, eEF2K inhibitor, NH125 treatment or eEF2K knockdown enhanced the efficacy of PD-1 mAb therapy in a melanoma mouse model. Conclusions Our results suggest that eEF2K may serve as a biomarker for predicting therapeutic response and prognosis in patients receiving anti-PD-1 therapy, reveal a vital role of eEF2K in regulating TIME by controlling PD-L1 expression and provide a potential combination therapeutic strategy of eEF2K inhibition with ICB therapy.
SYSTEMIC THROMBOEMBOLISM SECONDARY TO ACUTE MYOCARDIAL INFARCTION IN A PATIENT WITH CORONAVIRUS DISEASE
Authors: Takeshi Yamada, Soichiro Washimi, Norimasa Taniguchi, Shunsuke Nakajima, Tetsuya Hata, Akihiko Takahashi
Journal: Journal of the American College of Cardiology (2022)
FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
Authors: David Berg, Stephen D. Wiviott, Itamar Raz, Petr Jarolim, Erica L. Goodrich, Ofri Mosenzon, Avivit Cahn, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John PH Wilding, Ingrid Gause-Nilsson, Ann Hammarstedt, Jan Oscarsson, Marc Steven Sabatine, David A. Morrow
Journal: Journal of the American College of Cardiology (2022)
CLINICAL PROFILES OF HOSPITALIZED PATIENTS DIAGNOSED WITH ATRIAL FIBRILLATION IN MIDDLE EASTERN PATIENTS: ANALYSIS FROM THE JORDAN ATRIAL FIBRILLATION (JOFIB) STUDY
Authors: Nazih N. Kadri, Ahmed Abdulelah, Zaid A. Abdulelah, Mahmoud Obeidat, Mohammad Khasawneh, Abdullah Al-Kasasbeh, Yahya Ismail, Mohammed Al-Hiari, Dina Shaban, Zainab Salahat, Ayman J. Hammoudeh
Journal: Journal of the American College of Cardiology (2022)
INTRAOPERATIVE RESIDUAL LESION SCORE IS ASSOCIATED WITH POST-DISCHARGE TRANSPLANT-FREE SURVIVAL AND FREEDOM FROM UNPLANNED REINTERVENTIONS FOLLOWING CONGENITAL CARDIAC SURGERY
Authors: Aditya Sengupta, Kimberlee Gauvreau, Katherine Kohlsaat, Pedro J. del Nido, Meena Nathan
Journal: Journal of the American College of Cardiology (2022)
16P Checkpoint modification of BTLA-HVEM-LIGHT signaling by HSV-1 glycoprotein D (gD) improves vaccine-induced CD8+ T cell responses in pre-clinical cancer models
Authors: A. Luber, X. Zhou, Z. Xiang, W. Giles-Davis, C. Magowan, H.C. Ertl
Journal: Annals of Oncology (2022)